Stay updated with breaking news from Eric Jonasch. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Although renal cell carcinoma remains a difficult-to-treat disease, with patients with clear cell histology experiencing a median overall survival of approximately 13 months and a 5-year overall survival rate of less than 10%, updated results from clinical trials examining emerging therapeutic strategies have spurred optimism.
MD Anderson researchers are driven by a shared goal to end cancer. Here are 22 of their most impactful accomplishments from this past year.
When cancer is detected at an early stage, the rates of survival increase drastically, but today only a few cancer types are screened for.
When cancer is detected at an early stage, the rates of survival increase drastically, but today only a few cancer types are screened for.
/PRNewswire/ -- Vial introduces a new member joining their Oncology CRO Advisory Board. Eric Jonasch, MD, is a Genitourinary Medical Oncology Professor and...